Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Oligometastatic Prostate Cancer 1Colorectal Neoplasms 1Cholangiocarcinoma 1Bile Duct Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Photochemotherapy 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Dihematoporphyrin Ether 3Dexamethasone 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2regorafenib 2olaparib 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bile Duct Neoplasms × quemliclustat × Clear all
NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Big Ten Cancer Research Consortium

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡